BIRC3 and melanoma: Since ZFAND2A/AIRAP-siRNA-mediated knockdown affects cIAP2 protein stability in melanoma cells, ZFAND2A/AIRAP downregulation markedly enhances bortezomib anticancer activity in melanoma [38].